CRBSI Treatment Market

The global CRBSI Treatment Market is projected to be valued at USD 1,718.0 million in 2025 and is expected to reach USD 2,908 Million by 2035. Sales are projected to rise at a CAGR of 5.5% over the forecast period between 2025 and 2035. Vancomycin is expected to hold a 28.7% share in 2025, which is attributed to its widespread use against resistant Gram-positive infections. Injectable formulations will dominate the route of administration segment with a 69.1% market share, owing to their rapid therapeutic action and preference in critical care settings.